Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event
In a study of 29 patients (aged 0−16 years), performed between 23 February 2020 and 24 April 2020, a patient [age and sex not stated] was described, who developed SARS-CoV-2 infection while receiving treatment with brentuximab-vedotin and nivolumab for a refractory Hodgkin lymphoma [routes, dosages, duration of treatments to reaction onsets and outcome not stated]. The patient, who was diagnosed with refractory Hodgkin lymphoma started receiving immunotherapy with brentuximab-vedotin and nivolumab. However, the patient developed SARS-CoV-2 infection.
Reference
- Bisogno G, et al. Clinical Characteristics and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Italian Pediatric Oncology Patients: A Study From the Infectious Diseases Working Group of the Associazione Italiana di Oncologia e Ematologia Pediatrica. Journal of the Pediatric Infectious Diseases Society 9: 530-534, No. 5, Nov 2020. Available from: URL: 10.1093/jpids/piaa088 [DOI] [PMC free article] [PubMed]